# A New Way to    Detect Cancer      DELFI at AACR 2023

As a next-generation liquid biopsy company, DELFI Diagnostics is developing a rich pipeline of products designed to save lives by detecting cancer at its earliest stages. Our whole-genome fragmentomics platform is capable of supporting a broad range of high-performing applications to address major unmet medical needs in cancer.

Come see our presentations at AACR or stop by Booth 3355 to learn more about DELFI and our rigorous, sustainable approach to delivering new, better solutions to patients, providers, and health systems.

### ORAL PRESENTATIONS

#### [**Prospective evaluation of cell-free DNA fragmentomes for lung cancer detection**](https://www.abstractsonline.com/pp8/#!/10828/presentation/4904)

**Session Title:** Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities  
**Session Date/Time:** 4/18/23, 2:52 PM – 3:07 PM ET  
**Room:** W304 E-H – Convention Center  
[_Download Slides_](https://delfidiagnostics.com/wp-content/uploads/2023/04/Velculescu_AACR-2023_Slides.pptx.pdf)

#### [**Cell-free DNA fragmentation profiling for monitoring therapeutic response in metastatic colorectal cancer**](https://www.abstractsonline.com/pp8/#!/10828/presentation/3283)

**Session Title:** Increasing the Clinical Utility of Cell-Free DNA Testing  
**Session Date/Time:** 4/18/23, 3:52 PM – 4:07 PM ET  
**Room:**  Valencia D – Convention Center  
[_Download Slides_](https://delfidiagnostics.com/wp-content/uploads/2023/04/Alipanahi_AACR-2023_Slides.pdf)

### POSTER PRESENTATIONS

#### [**Early detection of ovarian cancer using cell-free DNA fragmentomes**](https://www.abstractsonline.com/pp8/#!/10828/presentation/5001)

**Session Title:** Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment  
**Session Date and Time:** 4/16/23, 1:30 PM – 5:00 PM ET  
**Location:** Section 28  
**Poster Board Number:** 15  
[_Learn More_](https://www.abstractsonline.com/pp8/#!/10828/presentation/5001)

#### [**CASCADE-LUNG: Validation of a blood-based assay that evaluates cell-free DNA fragmentation patterns to detect lung cancer**](https://www.abstractsonline.com/pp8/#!/10828/presentation/10505)

**Session Title:** Phase II and Phase III Clinical Trials in Progress  
**Session Date and Time:** 4/17/23, 9:00 AM – 12:30 PM ET  
**Location:** Section 46  
**Poster Board Number:** 26  
[_Download Poster_](https://delfidiagnostics.com/wp-content/uploads/2023/04/CASCADE-LUNG-TIP-Poster.pdf)